{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IART",
  "name": "Integra LifeSciences Holdings Corporation",
  "url": "https://frontierpicks.com/dossiers/IART/",
  "json_url": "https://frontierpicks.com/dossiers/IART.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only Argus's $25 sits above price, organic growth is +1.3%, and a binary Q2 print lands early August. Fresh entry pays fair value, not a setup.",
  "invalidation_trigger": "A weekly close below $17 loses the June post-Argus breakout shelf (built above the ~$17.43 consensus and old $17.83 high). Independently invalidated by a renewed manufacturing/recall/compliance 8-K, or an FY guide cut / the IEEPA tariff benefit flagged non-recurring at the early-August Q2 print.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-29",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Integra is a neurosurgery/regenerative medical-DEVICE turnaround, not a therapeutics biotech; any 'precision-therapeutics' label attached to it is wrong.",
    "Quality-system remediation is the standing tail risk: an FDA warning letter dated 2024-12-19 cited findings at Mansfield MA, Plainsboro NJ and Princeton NJ.",
    "Adjusted EPS carries an IEEPA tariff benefit cited by the CFO at the 2026-05-05 and 2026-07-29 prints; adjusted and GAAP lines diverge materially.",
    "Earnings cadence: Q1 printed 2026-05-05, Q2 on 2026-07-29, which places Q3 in late October. No print falls inside the next 30 days.",
    "Sell-side is Hold-heavy: 3 buy / 7 hold / 2 sell per Benzinga's aggregation as of 2026-08-08, with Argus $25 (2026-06-18) the lone high mark.",
    "Stuart Essig became President and CEO effective 2026-05-01; the operating record under this management team is only two quarters long."
  ],
  "body_markdown": "## Current Thesis\nThe shelf that defined this name since June is gone. Integra closed at $16.74 on 2026-08-21 — a Friday, so a weekly close beneath the ~$17 floor that the post-Argus advance built above the ~$17.43 consensus and the old $17.83 high. Two weeks earlier the last completed close was $17.25 with RSI(14) at 40.7; the reading is now 36.8 and the stock sits 15.7% below the $19.85 52-week high. The three-month price change has compressed to +10.9% from +23.9% as measured on 2026-08-07.\n\nWhat broke is the re-rating, not the P&L. The 2026-07-29 Q2 print delivered adjusted EPS $0.56 against $0.48 consensus and returned GAAP net income to $4.48M from a $484.07M year-ago loss. The tape gave the beat back inside three weeks. Every Hold-grade mark from the July coverage cluster — Citi Neutral $19 (2026-07-08), BMO Market Perform $19 (2026-07-09), UBS Neutral $19 (2026-07-28), Wells Fargo Equal Weight $18 (2026-07-30) — now sits above price rather than beneath it, and the 2026-08-04 street average of $19.56 (range $14–$27) is a ceiling the stock is walking away from.\n\nThe narrative is **dead** for the distressed-to-fair re-rating leg. What dates it: the 2026-08-21 weekly close below the June structure; the 2026-07-29 EPS beat that failed to hold; the completion of the initiation cycle on 2026-07-30 with no rating action surfacing since. What survives is a value and floor argument on the reaffirmed FY26 adjusted-EPS guide of $2.40–$2.50 — a slower, less crowded proposition with no dated resolution before the Q3 print on the existing cadence.\n\n## Bull Case\n- **Q2 2026 (2026-07-29): adjusted EPS $0.56 vs $0.48 consensus**, above the company's own guide, on revenue of $418.761M vs $415.61M a year earlier (+0.8% reported).\n- **GAAP profitability restored:** net income $4.48M against a $484.07M net loss in the year-ago quarter; operating margin 9.6% vs 7.9%; adjusted EBITDA margin 18.7%.\n- **The earnings guide held while the revenue range was trimmed:** FY26 adjusted EPS reaffirmed at $2.40–$2.50 on 2026-07-29, with the revenue reduction attributed to dollar strength rather than unit demand.\n- **Founder-era management is in the chair:** Stuart Essig was named President and CEO effective 2026-05-01 (announced with Q1 on 2026-05-05), alongside Michael McBreen as chief commercial officer — the governance change that anchors the pivot.\n- **Remediation converting to product:** management guided a controlled SurgiMend relaunch for Q4 2026 on the 2026-07-29 call.\n- **The street's own marks sit above the tape:** average target $19.56 as of 2026-08-04, with the low end of the range at $14 and Argus's Buy $25 (2026-06-18) at the top.\n\n## Bear Case\n- **Demand growth is absent for a second straight quarter:** organic revenue +1.3% at Q1 (2026-05-05), flat year over year at Q2 (2026-07-29).\n- **FY26 revenue guidance was cut** on 2026-07-29 from $1.662B–$1.702B to $1.654B–$1.695B, placing the range under the $1.676B consensus mid.\n- **Q3 guidance brackets consensus without clearing it:** adjusted EPS $0.53–$0.61 vs $0.56, sales $410M–$425M vs $418.1M.\n- **Earnings quality is policy-linked:** the CFO cited an IEEPA tariff benefit inside adjusted EPS at both the 2026-05-05 and 2026-07-29 prints, and the adjusted and GAAP lines diverge materially.\n- **Coverage is Hold-heavy and complete:** 3 buy / 7 hold / 2 sell per Benzinga's aggregation as of 2026-08-08; the four Neutral-grade marks all landed inside a 22-day window ending 2026-07-30, after the move.\n- **The compliance channel that caused the original collapse is unresolved history:** an FDA warning letter dated 2024-12-19 cited quality-system findings at Mansfield MA, Plainsboro NJ and Princeton NJ, following the 2024-09-06 Duraform recall and the 2024-09-20 surgical patties and strips recall.\n\n## Setup & Price Structure\n- Reference close $16.74 on 2026-08-21, 15.7% under the $19.85 52-week high, RSI(14) 36.8.\n- The June structure has failed: price is below the ~$17 shelf, below the ~$17.43 consensus zone, and below the $17.83 prior high the June breakout cleared. A weekly close back above $17.83 is what would mark structural repair; nothing between $16.74 and there is defended by a dated event.\n- Positioning observables, stated as observed: four Hold-grade initiations or target moves arrived 2026-07-08 through 2026-07-30, i.e. new coverage clustering into strength after a large advance; all four marks now sit above the tape; no rating action has surfaced since 2026-07-30; there is no earnings date inside the next 30 days; RSI at 36.8 with price under the shelf describes momentum decay with no squeeze mechanics — short-interest is not the driver here, the quarterly cadence is.\n- The 2026-07-29 beat produced no sustained bid. That is the observable that separates this from a routine pullback inside an intact trend.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-22 to 2026-09-21: no company-confirmed event.** On the established cadence — Q1 on 2026-05-05, Q2 on 2026-07-29 — nothing scheduled falls inside the window.\n- **~2026-10-28 (est.): Q3 2026 results.** First read on whether organic growth moves off flat, whether the FY26 revenue range is trimmed a second time, and whether the tariff benefit inside adjusted EPS is characterised as recurring.\n- **~2026-12-31 (est.): controlled SurgiMend relaunch, guided for Q4 2026** on the 2026-07-29 call.\n\n## What Would Change Our Mind\nThe June shelf has already given way, so the question is whether the break extends or repairs. Repair would look like a weekly close back above $17.83 — reclaiming the high the June breakout originally cleared — accompanied by organic growth off flat at the ~2026-10-28 Q3 print. Continuation of the break is defined by a weekly close below $16, which would complete the round-trip of the post-2026-06-18 Argus advance and leave price nearer the $14 low end of the 2026-08-04 target range than the $19.56 average. The fundamental clause that would independently confirm the downside read: a third consecutive quarter of flat-to-negative organic growth at Q3, an FY26 adjusted-EPS reset, or any of Citi, BMO, UBS or Wells Fargo marking down below $17. On the other side, a renewed 8-K or FDA action referencing recall, warning letter or production suspension would remove the turnaround premise regardless of where the multiple sits.\n\n## Correlation Notes\n- **Dollar sensitivity is explicit, not inferred:** the FY26 revenue cut on 2026-07-29 was attributed to a stronger US dollar, which links reported revenue to DXY direction over the September quarter.\n- **Trade-policy channel:** adjusted EPS carries an IEEPA tariff benefit per CFO commentary on 2026-05-05 and 2026-07-29, so tariff-regime changes hit the earnings line before they hit the revenue line.\n- **Reimbursement channel:** Tissue Technologies printed flat at Q2 with management citing reimbursement pressure, tying the SurgiMend recovery to skin-substitute payment policy rather than to surgical volumes.\n- **Peer group:** small- and mid-cap neurosurgery and regenerative device names move together on multiple and rate shifts; the company-specific variance here comes from quality-system remediation and supply reliability, which has no peer beta.",
  "first_seen": "2026-05-20",
  "last_analyzed": "2026-08-22T09:08:22+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}